human | Q5 |
P735 | given name | Jacques | Q941049 |
Jacques | Q941049 | ||
P106 | occupation | researcher | Q1650915 |
P21 | sex or gender | male | Q6581097 |
Q73497041 | (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen |
Q46448873 | 17alpha-hydroxylase/17,20-Lyase deficiency due to novel compound heterozygote mutations: treatment for tall stature in a female with male pseudohermaphroditism and spontaneous puberty in her affected sister |
Q33702124 | 17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes |
Q59355837 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk |
Q28200053 | A candidate prostate cancer susceptibility gene at chromosome 17p |
Q63363987 | A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening |
Q34015399 | A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics |
Q30541811 | A focus group study on breast cancer risk presentation: one format does not fit all |
Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
Q40368809 | A new alternative splice variant of BRCA1 containing an additional in-frame exon |
Q34150380 | A new insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency |
Q36152991 | A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers |
Q73867030 | A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX and 46,XY French-Canadians: evaluation of gonadal function after puberty |
Q36043159 | ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry |
Q37417780 | AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study |
Q42459420 | Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cells |
Q70030542 | Adrenal C19-5-ene steroids induce full estrogenic responses in rat pituitary gonadotrophs |
Q36073563 | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression |
Q35618307 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers |
Q39848414 | Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer |
Q43738941 | Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer |
Q41583427 | Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. |
Q68078523 | Androgens and breast cancer |
Q69449188 | Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer |
Q51051999 | Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles? |
Q35242849 | Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers |
Q28290684 | Assignment of the gene encoding the catalytic subunit C beta of cAMP-dependent protein kinase to the p36 band on chromosome 1 |
Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
Q36072765 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study |
Q36178189 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. |
Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
Q34801008 | Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
Q35957703 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer |
Q35523236 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers |
Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
Q42486668 | Atrial natriuretic factor does not affect basal, forskolin- and CRF-stimulated adenylate cyclase activity, cAMP formation or ACTH secretion, but does stimulate cGMP synthesis in anterior pituitary |
Q42509271 | Atrial natriuretic factor-induced cGMP accumulation in rat anterior pituitary cells in culture is not coupled to hormonal secretion |
Q34480647 | BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families |
Q24672715 | BRCA1 mutations in Ashkenazi Jewish women |
Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
Q71167609 | BRCA2 germline mutations in male breast cancer cases and breast cancer families |
Q42443275 | Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells |
Q42363834 | Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers |
Q34873841 | Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec |
Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
Q36998293 | COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration |
Q25257341 | CYP17 and breast cancer: no overall effect, but what about interactions? |
Q34963894 | Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
Q48368446 | Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues |
Q42473124 | Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. |
Q42486954 | Characteristics of the desensitization of growth hormone and cyclic AMP responses to growth hormone-releasing factor and prostaglandin E2 in rat anterior pituitary cells in culture |
Q40607915 | Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells |
Q40034935 | Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer |
Q44460221 | Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians |
Q34543730 | Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5'-termini in human placenta |
Q28294307 | Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells |
Q33587551 | Characterization of macaque 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase: structure and expression in steroidogenic and peripheral tissues in primate |
Q42445585 | Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro |
Q33222849 | Characterization of the guinea pig 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4-isomerase expressed in the adrenal gland and gonads |
Q67901776 | Characterization of the structure-activity relationships of rat types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5 -delta 4 isomerase by site-directed mutagenesis and expression in HeLa cells |
Q35169450 | Characterization of two mRNA species encoding human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17. |
Q59238197 | Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation |
Q36754871 | Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation |
Q40508451 | Codon 367 polymorphism of the human type I 3 beta-hydroxysteroid dehydrogenase/isomerase gene (HS5DB3). |
Q40873316 | Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy |
Q39697074 | Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience |
Q36839777 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers |
Q34394665 | Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction |
Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
Q24655824 | Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
Q42691997 | Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families |
Q36393232 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers |
Q35870067 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
Q37434133 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers |
Q34213403 | Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers |
Q41194578 | Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations |
Q42550093 | Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters |
Q44033897 | Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 273 delta AA in type II 3 beta-hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin |
Q34158693 | Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency |
Q28184736 | Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene |
Q31875103 | Crucial role of cytokines in sex steroid formation in normal and tumoral tissues |
Q34310104 | DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology |
Q40967909 | DHEA and peripheral androgen and estrogen formation: intracinology |
Q50883727 | DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. |
Q21144874 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers |
Q34337035 | Detection and functional characterization of the novel missense mutation Y254D in type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) gene of a female patient with nonsalt-losing 3 beta HSD deficiency |
Q72449361 | Detection of a novel mutation (stop 468) in exon 10 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians |
Q44500270 | Detection of frequent BglII polymorphism by polymerase chain reaction and TaqI restriction fragment length polymorphism for 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase at the human HSD beta 3 locus (1p11-p13). |
Q34356126 | Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21. |
Q58546894 | Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer |
Q71996206 | Dinucleotide repeat polymorphisms in the HSD3B2 gene |
Q52682549 | Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada). |
Q48524479 | Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. |
Q51554509 | Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing? |
Q42496991 | Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line |
Q33694914 | EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium |
Q34535264 | EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium |
Q51798328 | Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. |
Q69040335 | Effect of luteinizing hormone releasing hormone (LHRH) and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide on alpha-subunit and LH beta messenger ribonucleic acid levels in rat anterior pituitary cells in culture |
Q53243537 | Effect of the Women's Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testing. |
Q38022181 | Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population |
Q69093411 | Effects of sex steroids on regulation of the levels of C1 peptide of rat prostatic steroid-binding protein mRNA evaluated by in-situ hybridization |
Q69581264 | Electron microscopic autoradiographic localization of prolactin mRNA in rat pituitary |
Q35109610 | Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone |
Q73583253 | Estimated potency of Casodex: a problematic design |
Q37004792 | Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer |
Q33614244 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers |
Q37481884 | Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). |
Q36352389 | Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers |
Q54655246 | Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. |
Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
Q37102122 | Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk |
Q67864891 | Expression of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) and 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) in adipose tissue |
Q68060223 | Expression of liver-specific member of the 3 beta-hydroxysteroid dehydrogenase family, an isoform possessing an almost exclusive 3-ketosteroid reductase activity |
Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
Q43940234 | Family communication following BRCA1/2 genetic testing: a close look at the process |
Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
Q36087170 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
Q34325442 | Formation and degradation of dihydrotestosterone by recombinant members of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase family |
Q44652368 | From the gene to the clinic: prostate cancer death can now be an exception? |
Q42506316 | Full oestrogenic activity of C19-delta 5 adrenal steroids in rat pituitary lactotrophs and somatotrophs |
Q64087937 | Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control |
Q39308016 | Functional analysis of promoter variants in KU70 and their role in cancer susceptibility |
Q34317013 | Functional characterization of the novel L108W and P186L mutations detected in the type II 3 beta-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia. |
Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
Q40137431 | Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium |
Q28290206 | Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13 |
Q34570037 | Genetic discrimination and life insurance: a systematic review of the evidence |
Q72457355 | Genetic linkage mapping of HSD3B1 and HSD3B2 encoding human types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase close to D1S514 and the centromeric D1Z5 locus |
Q34372778 | Genetic linkage mapping of the dehydroepiandrosterone sulfotransferase (STD) gene on the chromosome 19q13.3 region |
Q71379341 | Genetic linkage mapping of the human steroid 5 alpha-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23-->p22 |
Q70484903 | Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA |
Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
Q46944912 | Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer |
Q35022825 | Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers |
Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
Q36422109 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium |
Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
Q42812130 | Genomic organization and expression of the mouse Brca2 gene |
Q38361077 | Glucocorticoids enhance activation of the human type II 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase gene |
Q36113782 | Gonadotropin-releasing hormone agonists in the treatment of prostate cancer |
Q64092231 | Health professionals' perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease |
Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
Q57694680 | High risk genes predisposing to prostate cancer development—do they exist? |
Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
Q34321130 | Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSD. |
Q30252854 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer |
Q36720814 | Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk |
Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
Q34038964 | Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions |
Q35541663 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer |
Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
Q37378034 | Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model |
Q50061932 | Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004-2014 in the U.S.: Further Evidence of the "Angelina Jolie Effect"? |
Q40979888 | Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13. |
Q40926664 | Induction of 3beta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines |
Q51596707 | Influence of the family cluster effect on psychosocial variables in families undergoing BRCA1/2 genetic testing for cancer susceptibility. |
Q37410472 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women |
Q39253143 | Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast Cancer |
Q47586106 | Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia |
Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
Q42476332 | Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16' alpha-chloro-3',17 beta-dihydroxy-estra-1',3',5'-(10')triene-7' alpha-yl] undecanamide in human breast cancer |
Q69749114 | Inhibitory effect of androgen on estrogen-induced prolactin messenger ribonucleic acid accumulation in the male rat anterior pituitary gland |
Q42498354 | Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells |
Q41753997 | Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells |
Q42525215 | Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells |
Q42478497 | Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1 alpha on apolipoprotein D and GCDFP-15 expression in human breast cancer cells |
Q33984042 | Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease |
Q72659351 | Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer |
Q42476720 | Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells |
Q36315402 | Is dehydroepiandrosterone a hormone? |
Q42527246 | Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs |
Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
Q42343135 | Life insurance: genomic stratification and risk classification |
Q24538779 | Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators |
Q47344785 | Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity |
Q51017140 | Localization and regulation of expression of the FAR-17A gene in the hamster flank organs. |
Q48148767 | Localization of 3 beta-hydroxysteroid dehydrogenase in rat brain as studied by in situ hybridization |
Q68889293 | Localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in rat gonads and adrenal glands by immunocytochemistry and in situ hybridization |
Q48045595 | Localization of BRCA1 gene expression in adult cynomolgus monkey tissues |
Q43455041 | Localization of peripheral benzodiazepine binding sites and diazepam-binding inhibitor (DBI) mRNA in mammary glands and dimethylbenz(a)antracene (DMBA)-induced mammary tumors in the rat. |
Q34240519 | Localization of the catalytic subunit C gamma of the cAMP-dependent protein kinase gene (PRKACG) to human chromosome region 9q13. |
Q48888669 | Localization of the endogenous benzodiazepine ligand octadecaneuropeptide in the rat testis. |
Q44439883 | Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer |
Q28301935 | Mapping of the HSD17B2 gene encoding type II 17 beta-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q24.1-q24.2 |
Q28183826 | Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7 |
Q38226150 | Medical genetic counseling for breast cancer in primary care: a synthesis of major determinants of physicians' practices in primary care settings |
Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
Q43735920 | Modulation by sex steroids and [D-Trp6, Des-Gly-NH2(10)]luteinizing hormone (LH)-releasing hormone ethylamide of alpha-subunit and LH beta messenger ribonucleic acid levels in the rat anterior pituitary gland |
Q57306222 | Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families |
Q34350282 | Molecular basis of congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency. |
Q34325834 | Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency. |
Q40454994 | Molecular basis of human 3 beta-hydroxysteroid dehydrogenase deficiency. |
Q34409441 | Molecular biology and genetics of the 3 beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family |
Q28301131 | Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family |
Q35635695 | Molecular cloning, cDNA structure and predicted amino acid sequence of bovine 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase |
Q24314861 | Molecular cloning, upstream sequence and promoter studies of the human gene for the regulatory subunit RII alpha of cAMP-dependent protein kinase |
Q48873935 | Multihormonal control of pre-pro-somatostatin mRNA levels in the periventricular nucleus of the male and female rat hypothalamus. |
Q72315005 | Multihormonal regulation of dehydroepiandrosterone sulfotransferase messenger ribonucleic acid levels in adult rat liver |
Q48256289 | Multiple factors controlling ACTH secretion at the anterior pituitary level |
Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
Q34268894 | Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in normal and tumoral target tissues |
Q50335703 | Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-hydroxylase/17-20-lyase deficiency in two French Canadian patients. |
Q33258847 | Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families |
Q46677306 | Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer |
Q33677871 | Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites |
Q49024646 | Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. |
Q39991531 | Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families |
Q39671238 | New concepts on the androgen sensitivity of prostate cancer. |
Q73276373 | New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enz |
Q37237352 | No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study |
Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
Q47154249 | No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families |
Q39357672 | No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result |
Q72879118 | No evidence of mutations in the genes for type I and type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) in nonclassical 3 beta HSD deficiency |
Q34299781 | Nonsalt-losing male pseudohermaphroditism due to the novel homozygous N100S mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene |
Q35752042 | Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures |
Q63328929 | Occurrence of cytochrome P450c17 mRNA and dehydroepiandrosterone biosynthesis in the rat gastrointestinal tract |
Q28565172 | Ontogenesis of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in the rat adrenal as revealed by immunocytochemistry and in situ hybridization |
Q34252341 | Ontogeny and subcellular localization of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) in the human and rat adrenal, ovary and testis |
Q42482863 | Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells |
Q28577186 | Opposite effects of prolactin and corticosterone on the expression and activity of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in rat skin |
Q43622332 | Ovarian 3 beta-hydroxysteroid dehydrogenase and sulfated glycoprotein-2 gene expression are differentially regulated by the induction of ovulation, pseudopregnancy, and luteolysis in the immature rat |
Q36280191 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
Q47143943 | PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. |
Q36417799 | Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges |
Q35737888 | Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
Q36543050 | Personalized medicine and access to health care: potential for inequitable access? |
Q34646957 | Perspective: prostate cancer susceptibility genes |
Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
Q34780052 | Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q47590869 | Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics |
Q68823228 | Potent antagonism between estrogens and androgens on GCDFP-15 expression and cell growth in the ZR-75-1 human breast cancer cells |
Q42491925 | Potent stimulatory effect of interleukin-1 alpha on apolipoprotein D and gross cystic disease fluid protein-15 expression in human breast-cancer cells |
Q36356727 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores |
Q37487782 | Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry |
Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
Q62583372 | Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort |
Q35147120 | Prostate cancer susceptibility genes: lessons learned and challenges posed |
Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
Q34236652 | Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities |
Q56603155 | Purification, Cloning, Complementary DNA Structure, and Predicted Amino Acid Sequence of Human Estradiol 17?-Dehydrogenase |
Q36512097 | RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies |
Q36009422 | RAD51B in Familial Breast Cancer |
Q72430442 | Rapid modulation of ovarian 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase gene expression by prolactin and human chorionic gonadotropin in the hypophysectomized rat |
Q57316334 | Rapid restriction fragment analysis for screening four point mutations of the Low-density lipoprotein receptor gene in French Canadians |
Q37524981 | Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies |
Q67676261 | Regulation of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase expression and activity in the hypophysectomized rat ovary: interactions between the stimulatory effect of human chorionic gonadotropin and the luteolytic effect of prolacti |
Q67589635 | Regulation of 3-ketosteroid reductase messenger ribonucleic acid levels and 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase activity in rat liver by sex steroids and pituitary hormones |
Q48319138 | Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture |
Q69263997 | Regulation of pro-gonadotropin-releasing hormone gene expression by sex steroids in the brain of male and female rats |
Q42484821 | Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer |
Q41017480 | Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells |
Q60895483 | Relative potencies of Flutamide and Casodex: preclinical studies |
Q44884896 | Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study |
Q54309392 | Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. |
Q48545504 | Return of research results: general principles and international perspectives. |
Q38717239 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers |
Q34089016 | Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues |
Q40632768 | SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation |
Q36545934 | SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival |
Q40662263 | Science behind total androgen blockade: from gene to combination therapy |
Q61118451 | Shared heritability and functional enrichment across six solid cancers |
Q64004349 | Shared heritability and functional enrichment across six solid cancers |
Q28248401 | Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate |
Q41669474 | Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells |
Q42511463 | Stimulation of growth hormone release and synthesis by estrogens in rat anterior pituitary cells in culture |
Q24310592 | Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads |
Q67882522 | Structure and expression of the genes encoding the enzymes for ovarian and peripheral steroidogenesis |
Q31138125 | Structure and tissue-specific expression of 3 beta-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues |
Q28572734 | Structure and tissue-specific expression of a novel member of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) family. The exclusive 3 beta-HSD gene expression in the skin |
Q28253733 | Structure of human type II 5 alpha-reductase gene |
Q31110971 | Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2. |
Q34118459 | Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues |
Q40707753 | Structure, regulation and role of 3 beta-hydroxysteroid dehydrogenase, 17 beta-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues |
Q70862262 | Structure-function relationships and molecular genetics of the 3 beta-hydroxysteroid dehydrogenase gene family |
Q40914971 | Structure-function relationships of 3 beta-hydroxysteroid dehydrogenase: contribution made by the molecular genetics of 3 beta-hydroxysteroid dehydrogenase deficiency. |
Q43076184 | Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36. The CRC/BPG UK Familial Prostate Cancer Study Coordinators and Collaborators. The EU Biomed Collaborators |
Q44044839 | Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor |
Q41473936 | Synthesis and antiestrogenic activity of diaryl thioether derivatives |
Q34428008 | Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution. |
Q68412019 | Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate |
Q37122297 | Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers |
Q33675997 | The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q64116004 | The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With or Mutations |
Q37578078 | The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers |
Q37401496 | The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q62583294 | The association between low-density lipoprotein cholesterol predicted by HMGCR genetic variants and breast cancer risk may be mediated by body mass index |
Q60487433 | The association between weight at birth and breast cancer risk revisited using Mendelian randomisation |
Q64239462 | The association between weight at birth and breast cancer risk revisited using Mendelian randomisation |
Q41226231 | The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds |
Q58674081 | The emergence of an ethical duty to disclose genetic research results: international perspectives |
Q72449349 | The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21 |
Q28288526 | The human type II 17 beta-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species |
Q28303450 | The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology |
Q38967942 | The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes |
Q45784223 | Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families |
Q53251612 | Use of dietary supplements among women at high risk of hereditary breast and ovarian cancer (HBOC) tested for cancer susceptibility. |
Q39672610 | Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers |
Q38814549 | VEXOR: an integrative environment for prioritization of functional variants in fine-mapping analysis |
Q41110061 | Variations of pre-proNPY mRNA in the arcuate nucleus during the rat estrous cycle |
Q72409585 | Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey |
Q72231232 | ["Intracrinology". Autonomy and freedom of peripheral tissues] |
Q39728256 | p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6. |
Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
Search more.